Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future

被引：1

作者：

Simunic, Marin ^{[1
,2
,3
]}

Mcgraw, Kathy ^{[1
,2
]}

Pavletic, Steven Z. ^{[1
,2
]}

Rashidi, Armin ^{[4
]}

机构：

[1] NCI, Immune Deficiency Cellular Therapy Program ID CTP, NIH, Bethesda, MD USA

[2] NCI, Myeloid Malignancies Program, NIH, Bethesda, MD USA

[3] Clin Hosp Ctr, Dept Hematol, Clin Internal Med, Split, Croatia

[4] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1100 Fairview Ave N,Thomas Bldg, Seattle, WA 98109 USA

来源：

SEMINARS IN HEMATOLOGY | 2024年 / 61卷 / 06期

基金：

美国国家卫生研究院;

关键词：

MDS; Intestinal; Microbiome; ARYL-HYDROCARBON RECEPTOR; GUT MICROBIOTA; CANCER; METABOLISM; MODULATION; TRYPTOPHAN; DOMINATION; HIPPURATE; BACTERIAL; IMMUNITY;

D O I：

10.1053/j.seminhematol.2024.10.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The intestinal microbiome has been mechanistically linked with health and many disease processes. Cancer is no exception. Both in solid tumors and hematologic malignancies, there is increasing evidence supporting the involvement of the intestinal microbiome in tumor development, disease progression, response to treatment, and treatment toxicity. Consistent with microbiome mediation of the immune system and the potent effect of the immune system on cancer, the most compelling evidence has been obtained in the setting of cancer immunotherapy. Here, we review the current state of knowledge about microbiome effects in myelodysplastic syndromes, identify gaps and challenges in related research, and provide insights for future work. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：442 / 448

页数：7

共 50 条

[21] Current status of epigenetic treatment in myelodysplastic syndromes [J].

Kuendgen, Andrea ;

Luebbert, Michael .

ANNALS OF HEMATOLOGY, 2008, 87 (08) :601-611

[22] Current and emerging strategies for management of myelodysplastic syndromes [J].

Saygin, Caner ;

Carraway, Hetty E. .

BLOOD REVIEWS, 2021, 48

[23] Current status of epigenetic treatment in myelodysplastic syndromes [J].

Andrea Kuendgen ;

Michael Lübbert .

Annals of Hematology, 2008, 87 :601-611

[24] Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives [J].

Yang, Minfeng ;

Oh, In Young ;

Mahanty, Arpan ;

Jin, Wei-Lin ;

Yoo, Jung Sun .

CANCERS, 2020, 12 (09) :1-23

[25] The current state and future perspectives of cannabinoids in cancer biology [J].

Sledzinski, Pawel ;

Zeyland, Joanna ;

Slomski, Ryszard ;

Nowak, Agnieszka .

CANCER MEDICINE, 2018, 7 (03) :765-775

[26] Renal denervation. Current state and future perspectives [J].

Kara, K. ;

Bruck, H. ;

Kahlert, P. ;

Plicht, B. ;

Mahabadi, A. A. ;

Konorza, T. ;

Erbel, R. .

HERZ, 2012, 37 (07) :746-753

[27] Subcellular Localization Signals of bHLH-PAS Proteins: Their Significance, Current State of Knowledge and Future Perspectives [J].

Greb-Markiewicz, Beata ;

Kolonko, Marta .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (19)

[28] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions [J].

Shyamala C. Navada ;

Lewis R. Silverman .

Current Hematologic Malignancy Reports, 2011, 6 :5-12

[29] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions [J].

Navada, Shyamala C. ;

Silverman, Lewis R. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) :5-12

[30] Involvement of the human microbiome in frequent cancers, current knowledge and carcinogenesis mechanisms [J].

Ait-Zenati, Fazia ;

Djoudi, Ferhat ;

Mehelleb, Dalila ;

Madaoui, Menad .

BULLETIN DU CANCER, 2023, 110 (7-8) :776-789

← 1 2 3 4 5 →